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Abstract
Background: HTLV-1 infection is currently restricted to endemic areas. To define the prevalence
of HTLV-1 infection in patients living in Italy, we first carried out a retrospective serological analysis
in a group of people originating from African countries referred to our hospital from January 2003
to February 2005. We subsequently applied a real time PCR on peripheral blood mononuclear cells
from subjects with positive or indeterminate serological results.
Methods: All the sera were first analysed by serological methods (ELISA and/or Western Blotting)
and then the peripheral blood mononuclear cells from subjects with positive or inconclusive
serological results were analyzed for the presence of proviral DNA by a sensitive SYBR Green real
time PCR. In addition, twenty HTLV-I ELISA negative samples were assayed by real time PCR
approach as negative controls.
Results: Serological results disclosed serum reactivity by ELISA (absorbance values equal or
greater than the cut-off value) in 9 out of 3408 individuals attending the Sexually Transmitted
Diseases Clinic and/or Oncology Department, and 2 out 534 blood donors enrolled as a control
population. Irrespective of positive or inconclusive serological results, all these subjects were
analyzed for the presence of proviral DNA in peripheral blood mononuclear cells by SYBR real time
PCR. A clear-cut positive result for the presence of HTLV-1 DNA was obtained in two subjects
from endemic areas.
Conclusion:  SYBR real time PCR cut short inconclusive serological results. This rapid and
inexpensive assay showed an excellent linear dynamic range, specificity and reproducibility readily
revealing and quantifying the presence of virus in PBMCs. Our results highlight the need to monitor
the presence of HTLV-1 in countries which have seen a large influx of immigrants in recent years.
Epidemiological surveillance and correct diagnosis are recommended to verify the prevalence and
incidence of a new undesirable phenomenon.
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Background
HTLV-1 (Human T-cell lymphotropic virus type 1) is etio-
logically linked with adult T-cell leukemia (ATL) [1-3].
HTLV-I infection is geographically confined in specific
areas such as Japan, the Caribbean basin, South America,
Sub-Saharian Africa, Melanesia and the Middle East [4].
Japanese area-related studies estimated about one million
people are currently infected by HTLV-I with 1–5% of
infected patients showing developing ATL [5]. Therefore,
the majority of HTLV-I infected subjects remain asympto-
matic throughout their lives even though up to7% of
HTLV-1 carriers may show chronic inflammatory neuro-
logical disease represented by HTLV-I- associated myelop-
athy/tropical spastic paraparesis (HAM/TSP) [1,3,6-9].
The relative percentage of malignant lymphoid prolifera-
tion and other associated diseases (such as HAM, uveites,
poliomiosites, arthritis, and alveolitis) varies widely in the
Caucasian population [4,10]. Hence, the transmission
routes (such as sexual intercourse, blood transfusion, tis-
sue transplantation and prolonged breastfeeding) [11-14]
and the increasing number of individuals emigrated from
endemic areas suggest that blood and tissue donors
should be screened to reduce the spread of infection [15-
17]. However, the epidemiology of HTLV-1 infection
could change in the near future [18] in the wake of immi-
gration. European countries, Italy particularly, represent
the main destination for immigrants from the Middle East
and Africa, making epidemiological surveillance highly
recommended to ascertain the prevalence and incidence
of HTLV-1 infection [16,19,20]. In the recent years, a
number of countries, including USA, Canada and France,
have introduced screening for blood donors to avoid a
possible spread of HTLV-1 infection by blood transfusion
[21].
To date, blood screening for HTLV-I has not been manda-
tory in Italy, but a more careful screening of the popula-
tion might be justified by several literature reports [22-
24]. Screening tests are usually based on antibody detec-
tion by ELISA and western blot, even though the relatively
large number of indeterminate results (up to 2.5%)
[21,25] needs to be confirmed by highly sensitive molec-
ular techniques [14,22]. In addition, to establish the pres-
ence of the genome and its modulation over time and/or
in the presence of specific therapy, PCR methods (com-
mercially available and in-house modified tests) represent
the gold standard useful to obtain a high level of specifi-
city and reproducibility in a short time [17,26-28].
Considering the need to update information on HTLV-1
incidence in Italy, we investigated the presence of HTLV-1
infection in a selected group of patients originating from
endemic areas using serological methods and a SYBR
Green real time PCR technique able to verify and quantify
the HTLV-1 proviral load.
Methods
Patients
From January 2003 to February 2005 we enrolled in the
study a group of HIV-1/2 negative 3408 recent immigrants
from African countries referred to the Sexually Transmit-
ted Diseases Clinic and/or Oncology Department (group
1) and a group of 534 blood donors (group 2) undergoing
laboratory analysis for serological diagnosis of other
infectious diseases. Recent immigrants were defined as
people stating they had lived in Italy for less than five
years at the time of HTLV-I serological analysis. All
patients, after informed consent, were screened for HTLV-
1 antibodies by ELISA assay (Vironostika HTLV-I/II,
BioMerieux, Boxtel, The Netherlands) as described by the
manufacturer. In addition, all ELISA borderline or posi-
tive samples and some randomly selected ELISA negative
samples were analyzed by Western-blot technique (Diag-
nostic Biotechnology HTLV WB, version 2.3, Genelabs
Diagnostic, Singapore) following the manufacturers' pro-
cedure.
Cell lines, plasmid and PBMC DNA extraction and 
purification
MT2 lymphoblastoid T cell line the most commonly used
cell line for HTLV-I production, previously characterized
as having 2.1 HTLV-I copies of virus/cell [29,30], Jurkat
and 8E5LAV cells (a cell line carrying one copy of HIV-1
genome/cell) [31] were obtained from the American Type
Culture Collection, (ATCC, Manassas, VA) and were kept
in RPMI 1640 (Gibco, Grand Island, NY) supplemented
with 10% of foetal calf serum (FCS; Gibco).
Peripheral blood mononuclear cells (PBMCs) from
twenty HTLV-1 negative patients and eleven patients with
indeterminate or positive HTLV-I serological assay were
isolated from whole blood by Ficoll-HistoPaque gradient
separation (Amersham Pharmacia). As previously
described [32], DNA was extracted and purified from
MT2, Jurkat, 8E5LAV and patients' PBMCs by DNAeasy
tissue kit (Qiagen) following the manufacturer's instruc-
tions. The DNA content of each sample was determined
by spectrophotometric analysis at 260/280 nm and stored
at -80°C until use. PBMC, MT2, 8E5LAV and Jurkat cell
pellets, corresponding to 5 × 106, were prepared and
stored at -80°C until use. Plasmid pHP1 is represented by
the pCR2.1-TOPO vector (Invitrogen, Paisley, UK) where
it was cloned the HTLV-I 117 bp amplicon as indicated by
the manufacturer. The plasmid pHP1 was purified by
Midi plasmid extraction kit (Qiagen) following the man-
ufacturer's procedure. Genomic and plasmid DNA con-
centration and purity were determined by
spectrophotometric analysis at 260/280 nm.BMC Infectious Diseases 2006, 6:41 http://www.biomedcentral.com/1471-2334/6/41
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Determination of HTLV-1 proviral DNA by SYBR green 
real time PCR
SYBR green real time PCR assay was performed in 20 μl
PCR mixture volume consisting in 2× Quantitect SYBR
green PCR Master Mix (Quiagen) containing HotStarTaq
DNA polymerase, 200 nM of each oligonucleotide primer
and 5 μl of DNA extracted from scalar dilution of MT-2
cell line (from 105 to 1 copies of HTLV-I genome) and
clinical samples.
HTLV-1 pol gene amplification was carried out as follows:
one cycle of 15 min at 95°C (hot-start PCR) and 45 cycles
in four step each (95°C for 5s, 60°C for 30 s, 72°C for 30
s, 76°C for 5 s). At the end of amplification cycles, melting
temperature was analyzed by a slow increase in tempera-
ture (0.1°C/s) up 95°C. The property elicited an accurate
analysis of the melting temperature curve of the amplified
fragments generated by real time PCR to determine the
detection and quantification of specific products [33].
Real time target amplification profile demonstrated a spe-
cific main peak with a melting temperature at 79.35°C.
HTLV-I pol primer sequences were: 5' GTG GTG GAT TTG
CCA TCG GGT TTT 3' and: 5' GTA CTT TAC TGA CAA
ACC CGA CCT AC 3'. The amplification with this pair of
oligonucleotides yielded a 117 bp pol fragment. Three rep-
licates were done for each scalar dilution for intra-assay
validation whereas three experiments were performed in
triplicate for inter-assay analysis. All MT-2 DNA scalar
dilutions were equalized at 600 ng of total DNA by Jurkat
cell DNA addition in all experiments. In addition, 600 ng
of total DNA from patients' PBMC or HTLV-I negative cell
lines were amplified. All patients' samples were also ana-
lysed by SYBR Green real-time PCR for globin gene in a
parallel run to check the equal amount in all samples
determined by spectrophotometric data as described [34].
All standard dilutions, controls and samples from patients
were run in duplicate and the average value of the copy
number was used to quantify HIV-1 DNA copies in PBMC.
All samples were run twice. The MT-2 cells were employed
as reference curve when the clinical samples were assayed.
Jurkat and 8E5LAV cell lines are employed as negative ref-
erence controls. HTLV-I DNA proviral load final quantita-
tive data were expressed as number of copies per 106
PBMC. Exact values were used for calculations, ruling out
decimal values.
Electrophoresis agarose gel, and Southern blot of PCR
amplicons were carried out as previously described [33].
The hybridization was performed using a specific digoxi-
genin labelled oligonucleotide probe. The hybridization
probe sequence is 5'-TAGCCCTATGGACAATCAAC -3'
Results
Serological analysis of patients' sera for specific HTLV-I 
antibodies
We analyzed the sera from 3408 immigrant African indi-
viduals HIV-1/2 negative, attending the Sexually Trans-
mitted Diseases Clinic and/or Oncology Department
(Group 1), and 534 blood donors by ELISA assay. Among
the patients selected, serum reactivity (absorbance values
equal or greater than the cut-off value) was disclosed in 9
out of 3408 patients (0.26%) and 2 out of 534 blood
donors (Group 2). Hence, we assayed the reactive serum
of these 11 individuals by HTLV-I specific Western-blot.
As shown in Table 1 and in Figure 1, Western Blot analysis
performed on these samples showed a clear serum reactiv-
ity to rgd21, p19, p24, p32, p36, gp46, p53 and rgp46-I
proteins in patient n° 3 and a serum reactivity to rgd21,
p19, p24, gp46, p53 and rgp46-I proteins in patient n° 7,
both belonging to Group 1. Both samples (n° 3 and n° 7)
were classified as positive on the basis of current guide-
lines [21]. In addition, a serum reactivity to p19 alone or
in the presence of p26 or p30 was observed in three
(patients n° 2, 6 and 9 of Group 1) out of the eleven and
the absence of serum reactivity to any viral proteins in six
(1, 4, 5, 8 of Group 1; 10 and 11 of Group 2) out of the
eleven (Table 1).
Western-blot assay results (Figure 1) demonstrated that
only 2 samples out of 11 (18.2%) were confirmed sero-
logically positive for HTLV-1 antibodies whereas 3 out of
11 (27.3%) were indeterminate and 6 out of 11 (54.5%)
were negative.
In particular the two positive samples with a clear antibody
pattern reacting to all HTLV-1 proteins belonged to patients
originating from Nigeria (samples n°3) and Ghana (sam-
ple n°7) respectively. Interestingly, none of blood donors
Table 1: Western blot results in the eleven serum samples with 
different level of reactivity by immnoenzymatic assay (ELISA).
WB results ELISA results
Pt. n°1 negative borderline
Pt. n°2 p19 borderline
Pt. n°3 gd21, p19, p24, p32, p36, gp46, p53, rgp46I positive
Pt. n°4 negative borderline
Pt. n°5 negative borderline
Pt. n°6 p19, 26 borderline
Pt. n°7 gd21, p19, p24, gp46, p53 and rgp46-I positive
Pt. n°8 negative borderline
Pt. n°9 p19, 30 borderline
Pt. n°10 negative borderline
Pt. n°11 negative borderline
WB positive: serum reactivity to envelope and gag proteins.
WB indeterminate: serum reactivity to one or two HTLV-1 proteins.
WB negative: lack of reactivity to viral proteins.
ELISA borderline: absorbance value equal to or greater (ranging from 
0.1 to 0.5 optical density) than the cut-off value
ELISA positive: absorbance value greater (ranging from 0.6 to >2.00 
optical density) than the cut-off valueBMC Infectious Diseases 2006, 6:41 http://www.biomedcentral.com/1471-2334/6/41
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tested were Western-blot reactive or indeterminate for
HTLV-I.
SYBR Green-based real time PCR analysis of HTLV-I 
indeterminate and reactive Western-blot patients
We evaluated indeterminate and reactive Western-blot
patients by in house SYBR green based Real time PCR
technique to determine the presence of HTLV-I proviral
genome in the peripheral blood mononuclear cells. This
technique was validated on scalar dilutions (from 105 to
10 HTLV-I genome equivalent copies) of MT2 cell line
genome containing 2.1 copies of proviral HTLV-I
genomes/cell (29,30) by using an oligonucleotide specific
pair able to amplify a 117 bp conserved region of HTLV-I
pol gene. The assay encompasses at least five orders of
magnitude with a high linear relationship (r2 > 0.99)
between the Ct values and the cell line input copies. The
specificity of amplified products was assessed by melting
curve analysis: all specific PCR amplicons showed the
same dissociation temperature (79.35C°).
The sensitivity of SYBR Green real time PCR was assessed
on MT-2 DNA scalar dilutions. The results demonstrated
that repeated testing (three replicates of all scalar dilutions
tested) of our assay disclosed 10 HTLV-I equivalent
genome copies in 100% of replicates (Table 2), whereas a
positive signal was not always detected when five copies
were assayed in our experimental conditions.
These data were confirmed when we analyzed the sensitiv-
ity of real time PCR by scalar dilutions of pHP1 plasmid
where the HTLV-I 117 bp pol fragment was cloned in a
plasmid vector. In this context, a real time PCR positive
signal was always detected at 10 plasmid copies (data not
shown). The specificity of SYBR Green real time PCR was
determined by Jurkat or 8E5LAV cellular DNA analysis.
These HTLV-I negative cells did not show any positive sig-
nal. Of note, this method shows a good intra- and inter-
assay reproducibility determined by scalar dilutions of
HTLV-I-positive MT-2 cell DNA equivalent genome analy-
sis. In particular, intra-assay reproducibility was evaluated
by three replicates of each point of scalar dilutions
between 105 and 10 HTLV-I genome equivalent copies.
The coefficient of variation (CV) of Ct was <3.8 % for all
scalar dilutions tested. The CV of copy number was <35%
for 10 copies and <25% for all more-concentrated dilu-
tions (from 105 to 102 copy/sample) (Table 2). The inter-
assay reproducibility was obtained by analysis of three dif-
ferent experiments, performed in triplicate, showing a CV
for Ct <4.1% for all MT-2 DNA dilutions analysed. The CV
of copy number was <40% for 10 copies and <25 % for all
more-concentrated dilutions (Table 2). Hence, we applied
this sensitive and specific technique on PBMCs DNA from
the eleven subjects previously selected for Western-blot
indeterminate or positive results. SYBR green based real
time PCR technique disclosed the HTLV-I genome in the
two Western-blot positive samples whereas the ELISA pos-
itive but Western blot indeterminate or negative samples
did not display any significant positive fluorescent signal.
In particular, the two real time PCR positive samples show
a HTLV-I genome copy number of 1.2 × 105 (n°3 patient)
and 5.9 × 102 (n°7 patient) per 106 PBMC genomes. Elec-
trophoresis agarose gel and Southern blot assay analysis
of amplicons indicated the presence of a specific band at
117 bp (Figure 2). An additional band representing an
unspecific fragment was observed in some samples (lanes
7–9). This fragment did not hybridize with HTLV-I spe-
cific probe and displayed a higher melting temperature
than HTLV-I specific products. In addition, no positive
signal was found in samples from twenty individuals (ran-
domly selected among the blood donors enrolled in the
study) with negative ELISA results.
Oncologic clinical investigation of patient n°3 revealed
that the positive sample belonged to a 27-year-old
Nigeria-born female prostitute living in Italy since 2001.
History-taking disclosed ATL disease with diffuse exfolia-
tive dermatitis followed by a rapid deterioration of the
patient's general condition, high white blood cell (WBC)
count (total WBCs: 54,070/mm3), a high number of lym-
phocytes (35,684/mm3), severe hypercalcemia (12.7
mEq/L; normal values: 4.2–5.2 mEq/L) and elevated LDH
plasma values (5,630 U/L; normal values: 230–450 U/L).
Hematological findings showing a monoclonal T-cell
lymphocytosis (95% of peripheral blood lymphocytes
were CD3+/CD4+/CD8/TCR α/β) confirmed the diagno-
sis of ATL.
Patient n°7, a 29-year-old Ghana-born female prostitute
living in Italy since 2000, monitored by the Sexually
Transmitted Diseases Clinic, showed normal white blood
cell count and number of lymphocytes, whereas no clini-
cal information was accessible because the patient, when
identified as HTLV-1 positive, refused any further control
and/or hematological monitoring.
Neither patient displayed any serological reactivity for
human immunodeficiency virus types 1 and 2, human
hepatitis B virus or human hepatitis C virus infection.
Discussion
The increasing rate of immigration towards European
countries and global tourism has determined a new
approach by national health committees to control the
spread of some infectious diseases previously confined to
specific endemic areas. In particular, this new global situ-
ation elicits European countries to monitor the local epi-
demiology of these emerging diseases. In Italy, HTLV-I
infection is still sporadic and is confined to immigrants
arriving from endemic areas. In particular, sexual trans-BMC Infectious Diseases 2006, 6:41 http://www.biomedcentral.com/1471-2334/6/41
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mission, HIV-1 seropositivity and intravenous drug abuse
are the preferential infection routes that may lead an
increase in HTLV-I infection incidence in the next few
years. Our study, focused on disclosing the presence of
HTLV-1 in Italy, revealed two HTLV-1 infections in a
selected group of individuals originating from African
countries. The specific presence of infection in Africa-born
patients demonstrated that the infection is noticeable in
individuals coming from endemic areas whereas no posi-
tive cases were found in the in Italy-born patient group
[35-39]. These data are in accordance with several studies
on HTLV-I epidemiology in Italy [10,18,19,40] even
though a high prevalence of HTLV-I infection was more
common in subjects co-infected with human immunode-
ficiency virus [19]. Our results disclosed HTLV-1 infection
in two HIV-1 negative women living in Italy from several
years. Even though we found a low prevalence (0.058%:
two out the 3408 individuals enrolled in our study) of
HTLV-1 infection, up-to-date information is necessary in
non endemic countries to gain more knowledge on the
spread of this virus.
In our study, both serological techniques used (ELISA and
WB) revealed clear-cut positive results in two samples but
Western blot did not rule out inconclusive results in three
serum samples from high risk individuals. However, the
finding of inconclusive results both by ELISA and immu-
noblotting analysis suggests the need to confirm virus
presence by molecular methods. The identification of spe-
cific viral sequences in infected cells is essential to confirm
the serological diagnosis in subjects with positive or inde-
terminate results [16,21,30]. In addition to determining
the distribution of virus in the organism, amplification
techniques also document the pathogenesis of infection
and the effectiveness of antiviral therapy [41,42].
The clinical interest in molecular biology assays for HTLV
diagnosis is increasing since proviral DNA levels represent
a measure of integrated genome [43] and a surrogate
marker of HTLV-I viral replication [44-46].
Our study also shows the application of a SYBR Green
based real time PCR committed to HTLV-I provirus detec-
tion and quantitation. We optimised the conditions of
SYBR Green real time PCR for HTLV-I DNA proviral detec-
tion with a high level of specificity (all 20 healthy blood
donors' samples did not show any detectable fluorescent
signal). Moreover, the assay has excellent dynamic range
from 105 to 101 copies with a detection limit established
at ten copies: a sensitivity comparable to other PCR for-
mats for HTLV-I. SYBR Green was chosen instead of differ-
ent real time approaches such as TaqMan or beacons to
generate fluorescence signals, for several reasons. In par-
ticular, SYBR Green is less expensive than labelled probes
that could also determine PCR artefacts beyond the 30th
cycle during the amplification. In addition, probe selected
sequences may be prone to specific mutations [47].
Table 2: Intra-assay and inter-assay analysis of Ct mean value of 
standard curves obtained with scalar dilution of MT2 cell line 
(from 105 to 1).
MT2 cell line N° copies/reaction Ct mean values ± SD CV
Intra-assaya
105 23.35 ± 0.7 3.0
104 25.91 ± 0.8 3.1
103 28.10 ± 1.0 3.5
102 31.78 ± 1.2 3.7
10 36.18 ± 1.3 3.5
1N D -
Inter-assayb
105 23.90 ± 0.7 2.9
104 26.12 ± 0.9 3.4
103 28.30 ± 1.1 3.8
102 32.10 ± 1.3 4.0
10 36.50 ± 1.4 3.8
1N D -
SD : standard deviation; CV: coefficient of variation; ND: not 
detectable
a For each sample, the Ct value is the average of results from three 
replicates.
b For each sample, the Ct value is the average of results from three 
different experiments performed in triplicate.
Western Blot analysis of samples with indeterminate or posi- tive serological results Figure 1
Western Blot analysis of samples with indeterminate or posi-
tive serological results. Lanes 1 and 2: control sera (positive 
and negative). Lanes 3 to 13 Western blot pattern of serum 
samples from patients 1 to 11 of table 1.BMC Infectious Diseases 2006, 6:41 http://www.biomedcentral.com/1471-2334/6/41
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The lack of any signal both in seronegative blood donors,
used as negative controls and in samples with inconclu-
sive serological results suggests a high specificity level.
Some literature data suggest that an indeterminate sero-
logical profile (seroreactivity to env proteins, in particular
to GD21) could reflect true HTLV-1 infection [16]. Inter-
pretation of doubtful HTLV-1/2 Western blot patterns has
therefore been enigmatic since the initiation of screening
for these viruses in the late 1980s and several hypotheses
have emerged in the last decade. Although HTLV-1
genomic sequences have been detected in the peripheral
blood lymphocytes (PBL) of seropositive individuals, pre-
vious studies repeatedly demonstrated that PBL from the
vast majority of HTLV-1/2 seroindeterminate individuals
are PCR negative for HTLV-1 (48). However the possibil-
ity of a molecular biology technique characterized by an
increased throughput over conventional PCR and quality
performance must be taken into consideration for its wide
application.
Since our SYBR green based real time PCR technique is a
specific and simple assay for quantitative detection of
HTLV-I proviral DNA, its application to monitor disease
progression and verify the effectiveness of therapy offers
an interesting option not only for first level diagnosis, but
also for ongoing epidemiological surveillance.
HTLV-1 proviral DNA quantification opens interesting
prospects. Cell-free viremia in plasma is not a prominent
aspect of HTLV-associated diseases, unlike HIV infection,
where the quantitative determination of RNA copies, the
main prognostic parameter for disease evolution, directly
mirrors viral replication [30]. Moreover, the determina-
tion of proviral load, in combination with other biomar-
kers, could be an important step in the pathogenesis of
HTLV-associated disease. In particular, a significant corre-
lation between the proviral load and neopterin concentra-
tion (related to inflammatory process in the spinal cord
lesion) has been found in the CSF of HAM/TSP patients
[44].
Our method may also be useful to analyze PBMCs from
blood donors with serological indeterminate results.
Blood donor screening for HTLV was introduced in Japan
in the mid 1980s, in the United States and Canada in
1988 and finally in France in 1991 [21], and even though
the probability of collecting blood products from a
viremic donor is extremely low, it is not negligible.
Conclusion
Even though our data demonstrated that HTLV-I infection
is mainly confined to African immigrants, the feasibility
of a simple and effective real time approach like our SYBR
Green real time PCR suggests a possible application to cut
short doubtful diagnosis of HTLV-1 infection and to mon-
itor proviral and viral load during the course of infection
and the efficacy antiviral therapy.
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Agarose gel electrophoresis and Southern blot of samples  amplified by SYBR Green real time PCR assay Figure 2
Agarose gel electrophoresis and Southern blot of samples 
amplified by SYBR Green real time PCR assay. In the upper 
part of the figure: the two positive HTLV-I samples (lanes 1 
and 11), the samples with HTLV-I indeterminate or positive 
serological assays (lanes 2–10), MT-2 representative cells 
scalar dilutions (from 102 to 104; lanes 12–14) and molecular 
weight markers (lane 15) are shown. The bottom of the fig-
ure shows the Southern blot assay. The non-specific bands 
exhibited in the HTLV-I negative samples (lane 7–9) repre-
sent non-specific products that both did not hybridize with 
the HTLV-I specific internal probe and showed an unrelated 
melting temperature in SYBR Green real time PCR.BMC Infectious Diseases 2006, 6:41 http://www.biomedcentral.com/1471-2334/6/41
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